Neurology & Brain Disorders Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Effect of CAFfeine on Cognition in Alzheimer's Disease

This Phase 3 study led by University Hospital, Lille is exploring whether caffeine can help slow memory loss and cognitive decline in people with early to moderate Alzheimer's disease. Participants in France receive caffeine treatment for 30 weeks to see if it can improve thinking and memory skills. If successful, caffeine could become a new option to help manage symptoms of Alzheimer's disease.

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Actinogen Medical is conducting a Phase 2 trial testing a daily 10 mg dose of Xanamem in people with mild or moderate dementia caused by Alzheimer's disease. The study, involving participants in the United States and Australia, aims to determine if Xanamem can improve cognitive function and daily abilities while keeping side effects manageable. This treatment may offer a new way to support patients’ brain health over a longer period.

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

PRInnovation GmbH is testing PRI-002 in a Phase 2 trial with adults who have mild cognitive impairment or mild dementia related to early Alzheimer's disease. The goal is to find out if this new drug can slow cognitive decline and enhance quality of life during the early stages of the disease. The study is active in several European countries and includes patients with the earliest symptoms.

Early Assessment of Autism Through Smart Tablet Gameplay

This completed study from the University of Strathclyde used a tablet-based game to help diagnose Autism Spectrum Disorder (ASD) in children by analyzing their movements during play. Involving 779 children from Sweden and the UK, the research aimed to create a faster and more objective way to identify autism. This tool could support earlier diagnosis and intervention for children with ASD.

5-Cog 2.0: A Pragmatic Clinical Trial

Albert Einstein College of Medicine is testing a new cognitive assessment tool called the 5-Cog paradigm to detect dementia and cognitive impairment in older adults during primary care visits. Recruiting in the United States, this study focuses on underserved populations and hopes to improve early diagnosis and care for cognitive problems. Better detection could lead to more timely support for patients and caregivers.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.